FDA to alter biosimilar ‘suffix’ policy

The US Food and Drug Administration (FDA) yesterday announced draft revisions to its policy on the naming of biosimilars, in an attempt to appease critics who say that renaming previously-licensed products is too expensive.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Careers

New UK High Court judge named as replacement for Justice Meade

23 September 2026 Following the prominent patent judge’s promotion to the Court of Appeal, the judiciary has appointed a King’s Counsel with 35 years’ experience as a barrister.

Careers

US firm hires litigation pro whose clients include Pfizer, Medtronic

23 September 2026 Varnum appoints the new partner to its litigation and ADR practice team as a partner in Michigan, bringing industry expertise in software, medical devices, robotics, consumer electronics and more.

Pharma

Behind the case: How Novartis defended its blockbuster Entresto in the UK

22 September 2026 After a run of UK decisions going against major pharma patents on plausibility, Novartis bucked the trend with Entresto. The company’s lead counsel from Bristows explains why and what patentees can take from the ruling.

More features

New UK High Court judge named as replacement for Justice Meade

US firm hires litigation pro whose clients include Pfizer, Medtronic

Behind the case: How Novartis defended its blockbuster Entresto in the UK

Oxford Nanopore scores urgent injunction at UPC in DNA sequencing fight

Benesch adds former McDermott IP practice head

Leading European patent litigator to join Carpmaels & Ransford

CIPA Congress: Sustainability is essential for the profession and the planet

Non-profit sues Cambrex over anticancer drug manufacturing trade secrets

FDA to alter biosimilar ‘suffix’ policy

More on this story

Editor's picks

Editor's picks

More features